<DOC>
	<DOC>NCT02635997</DOC>
	<brief_summary>Ibandronate is a third-generation biphosphonate with recognized antiresorptive efficacy by several international, randomized, double-blind, controlled trials. These studies have not included patients from central america, to the best of our knowledge. Therefore, this open-label, uncontrolled study, was set out to assess the clinical effects of a 6-m treatment course with Ibandronate plus vitamine D and Calcium on bone mineral density and health-related quality of life.</brief_summary>
	<brief_title>Antiresorptive Effects of a 6-m Treatment Course With Ibandronate Plus Supplementation of Vitamine D and Calcium in Central America</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Calcium, Dietary</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Women with a diagnosis of osteoporosis of atRisk Have a medical indication to receive Ibandronate+Vitamine D+Calcium Osteoporosis due to secondary causes</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>ibandronate</keyword>
	<keyword>vitamine D</keyword>
	<keyword>calcium</keyword>
	<keyword>bone mineral density</keyword>
	<keyword>health-related quality of life</keyword>
</DOC>